AI infrastructure DGrid launches an AI inference API supporting the x402 protocol, enabling on-chain payments via BNBChain.
ChainCatcher reports that the AI intelligent routing and infrastructure network DGrid AI has officially launched its AI inference API integrated with the x402 payment protocol. This API seamlessly combines payment logic with AI model calls for the first time, allowing developers and AI Agents to authorize, infer, and pay within a single API request lifecycle without managing complicated API Keys or prepaying into centralized accounts.
It is reported that this API currently supports BNB Chain (BSC) as the underlying settlement network. Leveraging the micropayment feature of the x402 protocol, the system enables extremely low-friction on-chain real-time settlement while ensuring absolutely controllable invocation costs. Additionally, the API is compatible with mainstream AI invocation methods, supporting streaming responses and real-time usage feedback, making it suitable for a variety of scenarios such as AI Agent model selection, inference billing, intelligent proxy, and multitasking execution.
DGrid stated that this move aims to completely break the prepaid barrier of traditional large model calls, providing programmable underlying payment infrastructure for building fully automated AI Agent economies (machine-to-machine transactions).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
